MicroRNA Panel for Colorectal Cancer Recurrence Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for colorectal cancer are inadequate in identifying patients at high risk for recurrence, leading to potential missed opportunities for early intervention and improved outcomes.
Innovation Solution
The use of a combination of microRNAs (miR-15a, miR-103, miR-148a, miR-320a, and miR-451) in circulating biological materials to predict recurrence risk, allowing for tailored monitoring and treatment strategies post-surgery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If surgery alone is used as standard care for early stage CRC patients, then treatment simplicity is maintained, but recurrence risk identification capability deteriorates
Solution Approach 1:
The patent applies preliminary action by performing microRNA analysis on circulating biological materials before making treatment decisions. This allows recurrence risk to be identified in advance, enabling proactive selection of patients who would benefit from adjuvant therapy rather than relying on surgery alone.
Solution Approach 2:
The patent introduces microRNA expression profiles as an intermediary diagnostic tool between surgery and recurrence monitoring. These molecular markers serve as mediators that provide information about recurrence risk, allowing clinicians to make informed decisions about additional therapy without directly observing cancer recurrence.
2Measurement precision
If microRNA analysis is performed to identify high-risk patients, then recurrence risk identification capability is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies segmentation by analyzing specific individual microRNAs (miR-15a, miR-103, miR-148a, miR-320a, miR-451) rather than attempting to measure all possible molecular markers. This segmented approach to biomarker analysis reduces diagnostic complexity while maintaining accurate recurrence risk identification capability.
Solution Approach 2:
The patent utilizes parameter changes by measuring expression levels of specific microRNAs in circulating biological materials. This shifts the diagnostic parameter from anatomical or clinical observations to molecular expression levels, enabling more precise recurrence risk assessment through quantifiable molecular data.
3Reliability
If adjuvant therapy is provided to high-risk patients, then survival benefit is improved, but treatment intensity increases
Solution Approach 1:
The patent applies local quality by providing adjuvant therapy selectively to specific patient subgroups identified as high-risk through microRNA analysis, rather than applying intensive treatment to all patients. This localized approach ensures that increased treatment intensity is applied only where it provides survival benefit, optimizing the balance between reliability and treatment burden.
Data Source
AI summary
In certain aspects, the disclosure relates to methods of predicting recurrence of colorectal cancer by using a combination of microRNAs in the circulation, wherein the microRNAs are selected from the group consisting of miR-15a, miR-103, miR-148a, miR-320a, miR-451 and miR-596. In other aspects, the disclosure relates to methods of treating colorectal cancer by administering a therapeutic agent after determining an increased risk of recurrence.